Primary prevention of cardiovascular disease is the least expensive and most efficacious form of disease intervention. It not only provides comprehensive control of cardiovascular risk factors, but also reduces the incidence of cardiovascular events. It is particularly effective in the control of atherosclerotic disease. Since thrombosis is a common pathway for cardiovascular events, inhibiting thrombosis is the last link in the chain of cardiovascular risk factor interventions, thus making the control of cardiovascular risk factors such as blood pressure, lipids and blood glucose more effective. Effective response to crisis In fact, primary prevention of cardiovascular disease refers to preventive measures taken before the disease occurs or when the disease is in subclinical stage to control or reduce cardiovascular disease risk factors, prevent cardiovascular events, and reduce population morbidity. More than 75% of the cardiovascular diseases that cause disability and death are atherosclerotic diseases. According to the latest epidemiological data, the prevalence of diabetes in China is close to 10%, reaching 92.4 million people, dyslipidemia and hypertension reached 200 million people respectively; just maintaining this level of risk factors, cardiovascular events including stroke and coronary heart disease from 2010-2030 is estimated to reach 21 million cases/year, and deaths will soar to 8 million/year. In the face of these alarming figures, medical workers in China must take the first solid step towards this type of “health crisis”. In early 2008, Minister of Health Chen Zhu proposed the strategic plan of “Health China 2020”, which aims to improve people’s health and focuses on solving the main problems that endanger the health of urban and rural residents. The strategy aims to improve the health of the people and focus on solving the major problems that are harmful to the health of urban and rural residents. The Yellow River Estuary Cardiovascular Disease Forum series of academic activities is a strong response and highlights the great task of this health cause, which will greatly improve the attention of cardiovascular doctors to the “health crisis” and the level of diagnosis and treatment, and will also play a positive role in the comprehensive prevention and treatment of vascular diseases in the city. We not only consider the strength of the evidence-based recommendations, but also take into account the relative lack of health resources, emphasizing the screening of common cardiovascular risk factors (blood pressure, blood glucose, lipids), and the cost-effectiveness ratio of drug recommendations, putting primary prevention into practice and “starting at the source”. It not only gives clear recommendations and guidance strategies for the screening and assessment of risk factors and the management and intervention of blood pressure, blood glucose, lipids, smoking and other major risk factors for cardiovascular events, but also makes clear recommendations for aspirin, the only antiplatelet drug with substantial evidence-based medical evidence and recommended by guidelines. The recommendations for aspirin, the only antiplatelet drug with substantial evidence-based medical evidence and guideline recommendations, will undoubtedly be effective in guiding clinicians in the rational primary prevention of cardiovascular disease. Clinically, aspirin is the only antiplatelet drug recommended by domestic and international guidelines for primary prevention of cardiovascular disease, and its clinical use has been well documented for nearly 100 years. Based on comprehensive prevention We understand that atherosclerotic disease, which covers coronary heart disease, stroke, abdominal aortic aneurysm, and peripheral arterial disease, is the leading cause of disability and death from cardiovascular disease. Unfortunately, there is no cure for atherosclerotic disease, highlighting the importance of primary prevention. According to a recent survey on primary prevention of aspirin in 4 cities nationwide, the rate of aspirin use in high-risk cardiovascular patients was only 14%, and the rate of use in high-risk cardiovascular diabetic patients was less than 1/3. The reasons for this are, on the one hand, the lack of awareness of primary prevention of cardiovascular disease among certain physicians; on the other hand, there may be one or more concerns about the bleeding side effects of aspirin, thus limiting the comprehensive intervention of primary prevention of cardiovascular disease. comprehensive interventions for primary prevention of diseases. In view of the severe health form in China, more to promote the migration of China’s cardiovascular disease prevention and treatment front, initiated by the Cardiovascular Physicians Branch of the Chinese Medical Association, joint cardiovascular, neurology, peripheral vascular disease, nephrology experts to discuss, and finally reached the Chinese expert consensus on primary prevention of cardiovascular disease, and to guide the clinical practice of China, especially primary care workers. It not only prescribes the right medicine, but also finds the key and grasps the key. At the same time, it lays a solid foundation for raising the health awareness of all people, helping readers to initially understand the basics of primary cardiovascular prevention, improving compliance, and opening up a new situation of comprehensive prevention by grasping the source. Professor Hu Da Yi also emphasized that it is not a question of whether aspirin should be used, but how to apply it more safely, and finding the right group of people with more benefits than risks becomes the key to applying aspirin. In particular, we call on the community to pay more attention to primary prevention of cardiovascular disease, and to change the status quo of the disease in China through primary prevention and comprehensive prevention, so that people can benefit from it.